Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.
Hiroaki MatsuuraHisao HigoTadahiro KuribayashiAkihiko TamaokiTakamasa NakasukaMari UnoGo MakimotoKiichiro NinomiyaMasanori FujiiKammei RaiEiki IchiharaKatsuyuki HottaNobuaki MiyaharaMasahiro TabataYoshinobu MaedaKatsuyuki KiuraKadoaki OhashiPublished in: Thoracic cancer (2024)
The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.
Keyphrases
- epidermal growth factor receptor
- pulmonary tuberculosis
- mycobacterium tuberculosis
- advanced non small cell lung cancer
- tyrosine kinase
- combination therapy
- small cell lung cancer
- middle aged
- community dwelling
- case report
- physical activity
- risk factors
- hiv aids
- radiation therapy
- mesenchymal stem cells
- human immunodeficiency virus
- rectal cancer